Richard Wright, MD
Advanced Heart Failure and Transplant Cardiology · Santa Monica, CANPI 1770580151
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,363,032 of the $1,694,494 with a category attached, or 80.4%. 49 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 24.6% of the total. Among advanced heart failure and transplant cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,072 payments — averaging $817.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$418K
- Amgen$347K
- Boehringer Ingelheim$301K
- Alnylam Pharmaceuticals Inc.$149K
- Novartis$138K
- AstraZeneca$96K
- plus $246K from 43 others
Across 1 payment — averaging $25,005 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$25K
What the payments were for
- Consulting fees$120,5927%
- Speaking & faculty fees$1,363,03280%
- Travel & lodging$165,77010%
- Food & beverage$45,0463%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,694,494 in reported general payments places this provider in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 215 | $5,360,835 |
| CamzyosMavacamten | 129 | $992,186 |
| JardianceEmpagliflozin | 320 | $375,741 |
| EliquisApixaban | 300 | $365,269 |
| EntrestoSacubitril/Valsartan | 220 | $258,490 |
| VyndaqelTafamidis Meglumine | 11 | $245,812 |
| Repatha SureclickEvolocumab | 215 | $223,534 |
| FarxigaDapagliflozin Propanediol | 111 | $134,082 |
| MounjaroTirzepatide | 69 | $83,331 |
| Praluent PenAlirocumab | 86 | $69,204 |
| OzempicSemaglutide | 48 | $61,827 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 217 | $58,621 |
| WegovySemaglutide | 35 | $49,673 |
| PradaxaDabigatran Etexilate Mesylate | 141 | $42,784 |
| XareltoRivaroxaban | 30 | $36,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis, Vyndaqel | $7,858 | $5,971,916526 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $417,688 | $992,186129 claims |
| Boehringer IngelheimJardiance, Pradaxa | $300,713 | $418,524461 claims |
| NovartisEntresto | $137,939 | $258,490220 claims |
| AstraZenecaFarxiga, Crestor, Lokelma | $96,172 | $158,052141 claims |
| Novo NordiskOzempic, Wegovy | $22 | $111,50083 claims |
| Lilly USA, LLCMounjaro | $30,367 | $83,33169 claims |
| Johnson & JohnsonXarelto | $614 | $36,99330 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $39,212 | $22,86026 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $51 | $5,88211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in Santa Monica
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Rajeev Mohanla Jolla$357K
- Marcus UreySan Diego$341K
- Munir JanmohamedSacramento$314K
- Barry GreenbergSan Diego$270K
- Ronald WittelesStanford$251K
- Gurpreet SodhiSacramento$241K
- Brian JaskiSan Diego$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.